Insider Selling: Tempus AI, Inc. (NASDAQ:TEM) CAO Sells 6,059 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) CAO Ryan M. Bartolucci sold 6,059 shares of the stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $80.00, for a total value of $484,720.00. Following the completion of the sale, the chief accounting officer now owns 47,000 shares of the company's stock, valued at approximately $3,760,000. This trade represents a 11.42 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Tempus AI Stock Performance

Shares of TEM traded up $5.69 during mid-day trading on Monday, hitting $89.44. The stock had a trading volume of 25,048,636 shares, compared to its average volume of 12,947,475. The company's fifty day simple moving average is $47.46 and its two-hundred day simple moving average is $50.72. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55. Tempus AI, Inc. has a fifty-two week low of $22.89 and a fifty-two week high of $91.45.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. Guggenheim assumed coverage on Tempus AI in a research note on Monday, December 9th. They issued a "buy" rating and a $74.00 target price for the company. Needham & Company LLC restated a "buy" rating and set a $56.00 price objective on shares of Tempus AI in a research note on Tuesday, January 14th. Stifel Nicolaus lowered Tempus AI from a "buy" rating to a "hold" rating and raised their price objective for the company from $45.00 to $65.00 in a research note on Monday, November 11th. Bank of America raised their price objective on Tempus AI from $52.00 to $54.00 and gave the company a "neutral" rating in a research note on Friday, December 13th. Finally, Wolfe Research began coverage on Tempus AI in a research note on Friday, December 13th. They set an "outperform" rating and a $60.00 price objective for the company. Four research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $58.55.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. First Horizon Advisors Inc. acquired a new position in shares of Tempus AI in the 3rd quarter worth approximately $30,000. Operose Advisors LLC acquired a new position in shares of Tempus AI in the 4th quarter worth approximately $25,000. Farther Finance Advisors LLC bought a new stake in shares of Tempus AI in the 4th quarter worth approximately $34,000. Prestige Wealth Management Group LLC lifted its holdings in shares of Tempus AI by 910.4% in the 4th quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company's stock worth $36,000 after purchasing an additional 965 shares during the last quarter. Finally, NewEdge Advisors LLC bought a new stake in shares of Tempus AI in the 4th quarter worth approximately $49,000. Institutional investors and hedge funds own 24.22% of the company's stock.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.